背景:背景:经前综合征(PMS)是女性人群中常见的疾病,对她们的身体和情绪健康产生不利影响。PMS的常规治疗可能有局限性和副作用,提示需要补充治疗方法。这个双盲,随机化,安慰剂对照试验旨在研究与安慰剂(PL)相比,个体化顺势疗法药物(IH)治疗PMS症状的疗效。
方法:这项研究招募了患有经前综合征(PMS)超过3个月的育龄女性参与者,从门诊部。参与者被随机分配接受IH或PL。测量结果包括缩短经前评估表(SPAF)问卷作为主要结果,经前期紧张综合征视觉模拟量表(PMTS-VAS)和经前期紧张综合征观察者评定量表-修订版(PMTS-OR)作为次要结局。在基线和每个月评估这些测量值,持续3个月。
结果:结果显示,与安慰剂组相比,IH组的SPAF总分在第2个月(-5.5±1.8,P=0.003)时具有统计学上的显着降低(F=11.340;P<0.001),和第3个月(-6.6±2.0,P=0.002)。此外,与安慰剂组相比,IH组的PMTS-VAS和PMTS-OR评分显著降低.Natrummuriaticum(n=4/30,13.3%)是该研究中最常用的药物。IH组发生4起不良事件(13.33%),安慰剂组出现6起不良事件(16.67%),没有严重事件的报告,在研究期间,参与者不需要额外的药物治疗.
结论:发现个体化顺势疗法药物显著有效,与安慰剂相比,在减轻PMS症状方面。需要进一步的独立复制来验证和证实这些发现,以及确定用于治疗PMS症状的最有效的顺势疗法药物。在那之前,在探索管理PMS的个性化和整体治疗策略时,临床医生可能会考虑这些发现。
背景:CTRI/2020/11/028,796,dt。02/11/2020。
BACKGROUND: Background: Premenstrual syndrome (PMS) is a common disorder among female population that adversely affects their physical and emotional well-being. Conventional treatments for PMS may have limitations and side effects, prompting a need for complementary therapeutic approaches. This double-blind, randomized, placebo-controlled
trial aimed to investigate the efficacy of individualized Homeopathic medicines (IH) in treating PMS symptoms in comparison to placebo (PL).
METHODS: This
study recruited female participants of reproductive age who had been experiencing premenstrual syndrome (PMS) for >3 months, from the Outpatient Department. The participants were randomly assigned to receive either IH or PL. The measured outcomes included the Shortened Premenstrual Assessment Form (SPAF) questionnaire as the primary outcome, and the Premenstrual Tension Syndrome Visual Analogue Scale (PMTS-VAS) and the Premenstrual Tension Syndrome Observer Rating Scale - Revised (PMTS-OR) as secondary outcomes. These measures were assessed at baseline and every month for 3 months.
RESULTS: The results showed a statistically significant reduction in total SPAF scores for the IH group compared to the placebo group (F = 11.340; P < 0.001) at month 2 (-5.5 ± 1.8, P = 0.003), and month 3 (-6.6 ± 2.0, P = 0.002). Additionally, there were significant reductions in PMTS-VAS and PMTS-OR scores in the IH compared to placebo group. Natrum muriaticum (n = 4/30, 13.3 %) was the most frequently indicated medicines in the
study. Four adverse events (13.33 %) occurred in the IH group, and six adverse events (16.67 %) in the Placebo group, with no serious events reported, and no additional medicinal treatment was required for participants during the
study period.
CONCLUSIONS: Individualized Homeopathic medicines were found to be significantly effective, compared to placebo in reducing PMS symptoms. Further independent replication is warranted to validate and corroborate these findings, as well as to identify the most effective Homeopathic medicines for treating PMS symptoms. Until then, clinicians may consider these findings when exploring personalized and holistic therapeutic strategies for managing PMS.
BACKGROUND: CTRI/2020/11/028,796, dt. 02/11/2020.